Moderna's mRNA Flu Vaccine Shows Positive Results in Phase 3 Trial
The mRNA-1010 vaccine generated a powerful response against 4 influenza virus strains compared to traditional flu shots.
It’s a great day for mRNA technology, particularly in the field of infectious diseases. Today, Moderna announced it had met its primary endpoints in a phase 3 trial for the company’s influenza vaccine, mRNA-1010.1 The vaccine had generated a powerful response against all 4 influenza virus strains compared to traditional influenza shots in late-stage trials.
Moderna has recently shows positive clinical results with a number of vaccines in its pipeline, including the completion of a biologics license application for RSV (mRNA-1345); completion of enrollment in its adult phase 3 trial of mRNA-1647, a vaccine for cytomegalovirus (CMV); and a phase 3 trial of mRNA-1283, the next COVID-19 vaccine.
The company is taking advantage of its vast research and development in mRNA technology to add to its robust pipeline that includes clinical benefits for cancer, 3 different rare diseases, and a number of infectious disease vaccines. Six of the company’s programs are in late-stage development, and Moderna plans on doubling its number of programs in phase 3 by 2025, launching up to 15 products in 5 years across cancer, rare disease, and infectious diseases.
On September 11, 2023, the FDA approved a supplemental biologics license application for the COVID-19 vaccine Moderna, now called Spikevax, for persons aged 12 years and older, with emergency use authorization in infants and children aged 6 months to 11 years.
For seasonal influenza, mRNA-1010 vaccine has demonstrated safety and tolerability profiles across all clinical trials, including 3 phase 3 trials, and independent data and safety monitoring boards have raised no concerns.
Moderna continues to work on a number of other influenza vaccine candidates that include additional hemagglutinin (HA) antigens for broader coverage of influenza A strains, as well as a candidate that incorporates HA and neuraminidase antigens to target proteins found in the influenza virus lifecycle, to decrease the potential of viral antigenic escape (mRNA-1020 and mRNA-1030).
Additionally, the company is working on a number of combination vaccines for influenza/COVID-19, and influenza/RSV.
Other viruses that Moderna is working on to develop vaccines for include the Epstein Barr virus; the herpes simplex virus; varicella zoster virus; the norovirus; and HIV.
This article originally appeared on Infection Control Today.
Reference
1. Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease. News Release. Moderna. September 13, 2023. Accessed September 15, 2023. https://investors.modernatx.com/news/news-details/2023/Moderna-Expands-the-Field-of-mRNA-Medicine-with-Positive-Clinical-Results-Across-Cancer-Rare-Disease-and-Infectious-Disease/default.aspx
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
Pfizer Announces Positive Top-Line Data for Abrysvo Immunization in Adults Aged 18 to 59 Years
April 9th 2024Abrysvo is currently approved to treat RSV-associated lower respiratory tract disease in adults aged 60 years and older, and in infants through the immunization of pregnant individuals.
